Abant Izzet Baysal University chool of Medicine, Department of Emergency Medicine, Bolu, Turkey.
Clinics (Sao Paulo). 2013 Apr;68(4):543-7. doi: 10.6061/clinics/2013(04)17.
This prospective study investigated the diagnostic significance of the N-terminal pro-brain natriuretic (NT-proBNP) and troponin I peptides in emergency department patients presenting with palpitations.
Two groups of patients with palpitations but without documented supraventricular tachycardia were compared: a group with supraventricular tachycardia (n = 49) and a control group (n = 47). Both groups were diagnosed using electrophysiological studies during the study period. Blood samples were obtained from all of the patients to determine the NT-proBNP and troponin I levels within the first hour following arrival in the emergency department.
The mean NT-proBNP levels were 207.74±197.11 in supraventricular tachyarrhythmia group and 39.99±32.83 pg/mL in control group (p<0.001). To predict supraventricular tachycardia, the optimum NT-proBNP threshold was 61.15 pg/mL, as defined by the receiver operating characteristic (ROC) curve, with a non-significant area under the ROC curve of 0.920 (95% CI, 0.86-0.97, p<0.001). The NT-proBNP cut-off for diagnosing supraventricular tachycardia had 81.6% sensitivity and 91.5% specificity. Supraventricular tachycardia was significantly more frequent in the patients with NT-proBNP levels ≥61.15 pg/mL (n = 44, 90.9%, p>0.001). The mean troponin I levels were 0.17±0.56 and 0.01±0.06 pg/mL for the patients with and without supraventricular tachycardia, respectively (p<0.05). Of the 96 patients, 21 (21.87%) had troponin I levels ≥0.01: 2 (4.25%) in the control group and 19 (38.77%) in the supraventricular tachycardia group (p<0.001).
Troponin I and, in particular, NT-proBNP peptide were helpful for differentiating supraventricular tachycardia from non- supraventricular tachycardia palpitations. Further randomized, large, multicenter trials are needed to define the benefit and diagnostic role of NT-proBNP and troponin I in the management algorithm of patients presenting with palpitations in emergency departments.
本前瞻性研究旨在探讨 N 端脑利钠肽前体(NT-proBNP)和肌钙蛋白 I 肽在急诊科出现心悸的患者中的诊断意义。
比较两组出现心悸但无记录的室上性心动过速的患者:一组为室上性心动过速组(n=49),一组为对照组(n=47)。两组均在研究期间通过电生理研究进行诊断。所有患者在急诊科到达后 1 小时内采集血样以确定 NT-proBNP 和肌钙蛋白 I 水平。
室上性心动过速组的平均 NT-proBNP 水平为 207.74±197.11pg/ml,对照组为 39.99±32.83pg/ml(p<0.001)。为预测室上性心动过速,最佳 NT-proBNP 阈值为 61.15pg/ml,这是由接收器工作特性(ROC)曲线定义的,ROC 曲线下面积无显著意义,为 0.920(95%置信区间,0.86-0.97,p<0.001)。诊断室上性心动过速的 NT-proBNP 截断值具有 81.6%的敏感性和 91.5%的特异性。NT-proBNP 水平≥61.15pg/ml 的患者室上性心动过速的发生率明显更高(n=44,90.9%,p>0.001)。有室上性心动过速的患者的平均肌钙蛋白 I 水平为 0.17±0.56pg/ml,无室上性心动过速的患者为 0.01±0.06pg/ml(p<0.05)。在 96 名患者中,有 21 名(21.87%)的肌钙蛋白 I 水平≥0.01:对照组 2 名(4.25%),室上性心动过速组 19 名(38.77%)(p<0.001)。
肌钙蛋白 I,尤其是 NT-proBNP 肽,有助于区分室上性心动过速与非室上性心动过速性心悸。需要进一步进行随机、大型、多中心试验,以确定 NT-proBNP 和肌钙蛋白 I 在急诊科出现心悸患者管理算法中的益处和诊断作用。